Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal ...

Scholar Rock Holding Corporation (NASDAQ:SRRK) has disclosed the presentation intended for the 43rd Annual J.P. Morgan Healthcare Conference in a recent filing with the U.S. Securities and Exchange ...

our highly selective myostatin inhibitor specifically designed for obesity and cardiometabolic disorders.” 2025 Strategic Priorities and Upcoming Milestones: Scholar Rock plans to focus on three ...

San Diego-based iBio has signed a backloaded agreement with its existing partner AstralBio for a preclinical anti-myostatin ...

Explore how inhibiting myostatin can promote muscle mass in men, addressing sarcopenia, GLP-1 medication effects, and aging ...

potentially reducing side effects compared to traditional myostatin inhibitors. Financially, Scholar Rock is well-positioned with a market cap of $4.19bn and a cash runway extending past initial ...

SAN DIEGO, Jan. 07, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO), an AI-driven innovator of precision antibody immunotherapies, in ...

By inhibiting Activin E ... This announcement follows the recent licensing of an anti-myostatin antibody from AstralBio by iBio, as well as the development of a bispecific antibody targeting ...

Activin E is believed to regulate energy balance, and inhibiting it could lead to therapeutics ... and our recently announced programs targeting Myostatin and Activin A as we build a pipeline ...